JPWO2020006631A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006631A5 JPWO2020006631A5 JP2021512244A JP2021512244A JPWO2020006631A5 JP WO2020006631 A5 JPWO2020006631 A5 JP WO2020006631A5 JP 2021512244 A JP2021512244 A JP 2021512244A JP 2021512244 A JP2021512244 A JP 2021512244A JP WO2020006631 A5 JPWO2020006631 A5 JP WO2020006631A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- repyrinast
- subject
- alcoholic steatohepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
Claims (6)
- レピリナストを含む、対象において小葉炎症又は非アルコール性脂肪性肝疾患を予防又は治療するための医薬組成物。
- レピリナストの量が、対象1kgあたり1mg～20mgの間である、請求項１に記載の医薬組成物。
- レピリナストの量が、対象1kgあたり3mg～10mgの間である、請求項2に記載の医薬組成物。
- レピリナストの量が、対象1kgあたり約10mgである、請求項3に記載の医薬組成物。
- 非アルコール性脂肪性肝疾患が非アルコール性脂肪性肝炎である、請求項1から4のいずれか一項に記載の医薬組成物。
- 非アルコール性脂肪性肝疾患が、非アルコール性脂肪性肝炎由来肝細胞癌である、請求項1から5のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694848P | 2018-07-06 | 2018-07-06 | |
| US62/694,848 | 2018-07-06 | ||
| US201962809351P | 2019-02-22 | 2019-02-22 | |
| US62/809,351 | 2019-02-22 | ||
| PCT/CA2019/050915 WO2020006631A1 (en) | 2018-07-06 | 2019-07-03 | Compositions and methods for treating non-alcoholic steatohepatitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535175A JP2021535175A (ja) | 2021-12-16 |
| JPWO2020006631A5 true JPWO2020006631A5 (ja) | 2022-07-12 |
| JP7399949B2 JP7399949B2 (ja) | 2023-12-18 |
Family
ID=69060680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512244A Active JP7399949B2 (ja) | 2018-07-06 | 2019-07-03 | 非アルコール性脂肪性肝炎治療のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11744808B2 (ja) |
| EP (1) | EP3817749A4 (ja) |
| JP (1) | JP7399949B2 (ja) |
| CN (1) | CN112654357B (ja) |
| CA (1) | CA3105850A1 (ja) |
| WO (1) | WO2020006631A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020191501A1 (en) * | 2019-03-27 | 2020-10-01 | Algernon Pharmaceuticals Inc. | Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders |
| WO2020191503A1 (en) * | 2019-03-27 | 2020-10-01 | Algernon Pharmaceuticals Inc. | Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders |
| IT202100014177A1 (it) * | 2021-05-31 | 2022-12-01 | Sunnutrapharma S R L | Utilizzo della istradefillina per ridurre la fibrosi d’organo |
| CN115778957B (zh) * | 2022-11-04 | 2024-06-21 | 天津中医药大学 | 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2175229C2 (ru) * | 1999-12-22 | 2001-10-27 | Научно-исследовательский институт фармакологии РАМН | Анксиолитическое средство |
| JP3885135B2 (ja) * | 2000-10-10 | 2007-02-21 | 幸彦 松田 | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 |
| RU2261709C2 (ru) * | 2003-08-15 | 2005-10-10 | Государственное учреждение Научно-исследовательский институт фармакологии Российской Академии медицинских наук | Психостимулирующее средство |
| MX2009010477A (es) * | 2007-03-30 | 2009-10-19 | Cardoz Ab | Nueva combinacion para su uso en el tratamiento de trastornos inflamatorios. |
| WO2009007679A2 (en) * | 2007-07-11 | 2009-01-15 | Cardoz Ab | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist |
| JPWO2012157290A1 (ja) | 2011-05-19 | 2015-02-23 | 富士化学工業株式会社 | 非アルコール性脂肪性肝炎の予防改善剤 |
| CA2864389A1 (en) * | 2012-02-20 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| RU2547141C1 (ru) * | 2014-02-28 | 2015-04-10 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | Способ получения n-(4-бромфенил)-n-(2-адамантил)амина (бромантана) |
| US20180271788A1 (en) * | 2015-12-11 | 2018-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Vesicle containing metallic nanoparticle and method for production thereof |
-
2019
- 2019-07-03 CN CN201980058395.1A patent/CN112654357B/zh active Active
- 2019-07-03 EP EP19829889.5A patent/EP3817749A4/en active Pending
- 2019-07-03 WO PCT/CA2019/050915 patent/WO2020006631A1/en unknown
- 2019-07-03 CA CA3105850A patent/CA3105850A1/en active Pending
- 2019-07-03 JP JP2021512244A patent/JP7399949B2/ja active Active
- 2019-07-03 US US17/258,402 patent/US11744808B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507914A5 (ja) | ||
| JP2018193377A5 (ja) | ||
| JP2021063088A5 (ja) | ||
| JP2008505857A5 (ja) | ||
| EP2636404A3 (en) | Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products | |
| JP2008533021A5 (ja) | ||
| JP2016530279A5 (ja) | ||
| JP2017515854A5 (ja) | ||
| JP2023076465A5 (ja) | ||
| JP2018503685A5 (ja) | ||
| MX2021010350A (es) | Composicion que comprende leuconostoc citreum wikim0104 para prevenir, mejorar o tratar la obesidad o la enfermedad del higado graso. | |
| JP2020111586A5 (ja) | ||
| JP2009541409A5 (ja) | ||
| JPWO2020006631A5 (ja) | ||
| JP2009502937A5 (ja) | ||
| DE602006016785D1 (de) | Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung | |
| EA200600626A1 (ru) | Композиция и лекарственная форма продолжительного выделения леводопы | |
| JP2018505218A5 (ja) | ||
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| JP2023078477A5 (ja) | ||
| JP2023055802A5 (ja) | ||
| JP2018513175A5 (ja) | ||
| WO2009041798A8 (es) | Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas. | |
| JP2018058769A (ja) | 医薬組成物 | |
| JPWO2020000092A5 (ja) |